» Articles » PMID: 22094905

Dysregulated Expression of Both the Costimulatory CD28 and Inhibitory CTLA-4 Molecules in PB T Cells of Advanced Cervical Cancer Patients Suggests Systemic Immunosuppression Related to Disease Progression

Overview
Specialty Oncology
Date 2011 Nov 19
PMID 22094905
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Cervical cancer (CC) occurs more frequently in women who are immunosuppressed, suggesting that both local and systemic immune abnormalities may be involved in the evolution of the disease. Costimulatory CD28 and inhibitory CTLA-4 molecules expressed in T cells play a key role in the balanced immune responses. There has been demonstrated a relation between CD28, CTLA-4, and IFN genes in susceptibility to CC, suggesting their importance in CC development. Therefore, we assessed the pattern of CD28 and CTLA-4 expression in T cells from PB of CC patients with advanced CC (stages III and IV according to FIGO) compared to controls. We also examined the ability of PBMCs to secrete IFN-gamma. We found lower frequencies of freshly isolated and ex vivo stimulated CD4 + CD28+ and CD8 + CD28+ T cells in CC patients than in controls. Loss of CD28 expression was more pronounced in the CD8+ T subset. Markedly increased proportions of CTLA-4+ T cells in CC patients before and after culture compared to controls were also observed. In addition, patients' T cells exhibited abnormal kinetics of surface CTLA-4 expression, with the peak at 24 h of stimulation, which was in contrast to corresponding normal T cells, revealing maximum CTLA-4 expression at 72 h of stimulation. Of note, markedly higher IFN-gamma concentrations were shown in supernatants of stimulated PBMCs from CC patients.

Conclusions: Our report shows the dysregulated CD28 and CTLA-4 expression in PB T cells of CC patients, which may lead to impaired function of these lymphocytes and systemic immunosuppression related to disease progression.

Citing Articles

Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer.

Li Y, Shen F, Tan Q, Chen Y, Gu Y Technol Cancer Res Treat. 2023; 22:15330338231208846.

PMID: 37908109 PMC: 10621300. DOI: 10.1177/15330338231208846.


The abscopal effect of immune-radiation therapy in recurrent and metastatic cervical cancer: a narrative review.

Ollivier L, Moreau Bachelard C, Renaud E, Dhamelincourt E, Lucia F Front Immunol. 2023; 14:1201675.

PMID: 37539054 PMC: 10394237. DOI: 10.3389/fimmu.2023.1201675.


Recurrent or primary metastatic cervical cancer: current and future treatments.

Gennigens C, Jerusalem G, Lapaille L, De Cuypere M, Streel S, Kridelka F ESMO Open. 2022; 7(5):100579.

PMID: 36108558 PMC: 9588874. DOI: 10.1016/j.esmoop.2022.100579.


Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer.

Gutierrez-Silerio G, Franco-Topete R, Haramati J, Navarrete-Medina E, Gutierrez-Franco J, Bueno-Topete M BMC Immunol. 2020; 21(1):9.

PMID: 32138659 PMC: 7059382. DOI: 10.1186/s12865-020-0341-9.


Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS).

Zhao Y, Qiao G, Wang X, Song Y, Zhou X, Jiang N Clin Transl Oncol. 2018; 21(6):721-728.

PMID: 30374838 DOI: 10.1007/s12094-018-1968-3.


References
1.
Ligers A, Teleshova N, Masterman T, Huang W, Hillert J . CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001; 2(3):145-52. DOI: 10.1038/sj.gene.6363752. View

2.
Diaz-Benitez C, Navarro-Fuentes K, Flores-Sosa J, Juarez-Diaz J, Uribe-Salas F, Roman-Basaure E . CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. J Clin Immunol. 2009; 29(4):532-44. DOI: 10.1007/s10875-009-9279-7. View

3.
June C, Ledbetter J, Linsley P, Thompson C . Role of the CD28 receptor in T-cell activation. Immunol Today. 1990; 11(6):211-6. DOI: 10.1016/0167-5699(90)90085-n. View

4.
Melichar B, Solichova D, Freedman R . Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer. 2006; 16(1):240-52. DOI: 10.1111/j.1525-1438.2006.00294.x. View

5.
Gaiotti D, Chung J, Iglesias M, Nees M, Baker P, Evans C . Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog. 2000; 27(2):97-109. DOI: 10.1002/(sici)1098-2744(200002)27:2<97::aid-mc5>3.0.co;2-v. View